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Summary
Background Adverse childhood experiences (ACEs) are associated with increased health risks across the life course. 
We aimed to estimate the annual health and financial burden of ACEs for 28 European countries.
Methods In this systematic review and meta-analysis, we searched MEDLINE, CINAHL, PsycINFO, Applied Social 
Sciences Index and Abstracts, Criminal Justice Databases, and Education Resources Information Center for 
quantitative studies (published Jan 1, 1990, to Sept 8, 2020) that reported prevalence of ACEs and risks of health 
outcomes associated with ACEs. Pooled relative risks were calculated for associations between ACEs and harmful 
alcohol use, smoking, illicit drug use, high body-mass index, depression, anxiety, interpersonal violence, cancer, 
type 2 diabetes, cardiovascular disease, stroke, and respiratory disease. Country-level ACE prevalence was calculated 
using available data. Country-level population attributable fractions (PAFs) due to ACEs were generated and applied 
to 2019 estimates of disability-adjusted life-years. Financial costs (US$ in 2019) were estimated using an adapted 
human capital approach.
Findings In most countries, interpersonal violence had the largest PAFs due to ACEs (range 14·7–53·5%), followed by 
harmful alcohol use (15·7–45·0%), illicit drug use (15·2–44·9%), and anxiety (13·9%–44·8%). Harmful alcohol use, 
smoking, and cancer had the highest ACE-attributable costs in many countries. Total ACE-attributable costs ranged 
from $0·1 billion (Montenegro) to $129·4 billion (Germany) and were equivalent to between 1·1% (Sweden and 
Turkey) and 6·0% (Ukraine) of nations’ gross domestic products.
Interpretation Availability of ACE data varies widely between countries and country-level estimates cannot be directly 
compared. However, findings suggest ACEs are associated with major health and financial costs across European 
countries. The cost of not investing to prevent ACEs must be recognised, particularly as countries look to recover 
from the COVID-19 pandemic, which interrupted services and education, and potentially increased risk factors for 
ACEs.
Funding WHO Regional Office for Europe.
Copyright © 2021 World Health Organization; licensee Elsevier. This is an Open Access article published under the 
CC BY NC ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, 
so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. 
This article shall not be used or reproduced in association with the promotion of commercial products, services or any 
entity. There should be no suggestion that WHO endorses any specific organisation, products or services. The use of 
the WHO logo is not permitted. This notice should be preserved along with the article’s original URL.
Introduction 
Awareness of the harms associated with adverse childhood 
experiences (ACEs) has increased substantially over the 
past two decades, supported by a proliferation of literature 
on the prevalence of ACEs and their relationships with 
poor life-course health.1 The term ACEs refers to various 
intensive stressors that can affect children while growing 
up, such as suffering mal treatment, witnessing violence 
in the home or community, and living with family 
difficulties (eg, parental substance abuse).2 Exposure to 
such stressors can influence children’s neurological, 
biological, and social development and increase their 
susceptibility to social difficulties (eg, low educational 
attainment), health-harming behaviours (eg, smoking), 
and mental and physical illness across the life course.3,4 
Increased awareness of the links between ACEs and 
multi-agency priorities has driven the development of 
policy and practice aimed at preventing ACEs and 
supporting those affected by them.5,6 However, as global 
attention and resources have diverted to addressing 
COVID–19, there are concerns that responses to the 
pandemic might have increased exposure to ACEs and 
exacerbated their effects.7,8 Restrictions imposed to 
manage the pandemic have confined children and 
families within homes, closed essential social networks 
and support structures, and increased risk factors for 
ACEs such as unemployment and parental stress. Nations 
must now address the challenge of recovery, with 
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investment choices being made in the face of a potential 
recession and competing priorities for funding. To 
support sound economic decision making, the costs of not 
investing in childhood must be recognised.
Until recently, little data were available on the 
economic costs of ACEs, with most studies focusing on 
individual adversity types such as child maltreatment.9 
However, a 2019 study estimated the annual burden of 
ACE exposure across ten risk factors for, and causes 
of, ill health to be US$581 billion in Europe and 
$748 billion in North America; equivalent to 2·7% of 
Europe’s and 3·5% of North America’s gross domestic 
product (GDP).10 Although these figures expose the 
immense costs associated with ACEs, more nuanced 
country-level data are required to support policy 
develop ment and decision making at a national level. 
Thus, estimates have since been published for some 
countries and regions. For example, in California, USA, 
the annual cost of ACEs across eight health risks and 
causes has been estimated to exceed $100 billion,11 
while in England and Wales annual costs across 
13 health risks and causes of ill health have been 
estimated at £43 billion.12 However, to our knowledge 
no cost estimates are available for other European 
countries.
Estimating the national costs of ACEs requires a 
measure of the prevalence of ACEs within a country’s 
population. In the past few years, the number of studies 
measuring ACEs has burgeoned with a bibliographic 
review finding that almost half of studies on ACEs 
published between 1998 and 2018 had been published 
since 2017.1 Although much research focuses on 
North American populations, studies are emerging 
from an increasing number of countries around the 
world, including many European countries. Thus, here 
we developed the approach used to produce continent-
level estimates for Europe and North America,10 to 
estimate the annual costs associated with ACEs 
in individual European countries. Using data from 
European studies, we calculated country-level popu-
lation attributable fractions (PAFs) for one and multiple 
ACEs across 12 health outcomes, including four risk 
factors (harmful alcohol use, smoking, illicit drug use, 
high body-mass index [BMI]; defined as ≥25 kg/m² in 
all included studies) and eight causes of ill health 
(depression, anxiety, interpersonal violence, cancer, 
type 2 diabetes, cardiovascular disease, stroke, and 
respiratory disease). We calculated the health 
and financial burden of ACEs for each of 28 countries 
using an adapted human capital method. The study 
does not intend to provide comparable estimates of 
ACE prevalence or ACE burden between countries, 
but rather to develop the best estimates for each country 
using available data.
Research in context
Evidence before this study
A rapidly expanding evidence base links adverse childhood 
experiences (ACEs) to poorer health and wellbeing across the life 
course. Exposure to ACEs can influence neurological and 
physiological development and increase vulnerability to the 
adoption of health-harming behaviours and development of 
mental illness and chronic disease. Such health effects impose 
major costs on both individuals and society. Our previous 
systematic reviews have examined the associations between 
ACEs and health outcomes and estimated the health and 
financial costs of ACEs at a regional level. Thus, the financial costs 
of ACEs across ten health risks and causes of ill health in 2017 
were estimated to be US$581 billion in Europe and $748 billion 
in North America; equivalent to 2·7% of Europe’s and 3·5% of 
North America’s regional gross domestic products (GDPs).
Added value of this study
With few country-level estimates of the health and financial 
cost of ACEs available, this study calculated such estimates for 
each of 28 European countries. We updated previous searches 
to identify additional literature on the prevalence of ACEs in 
country samples and their associations with health outcomes in 
European populations. We used meta-analyses to generate 
pooled relative risks for 12 health outcomes. ACE prevalence 
estimates were generated for each of 28 European countries 
using available data and were used to calculate country-level 
population attributable fractions for each outcome. 
ACE-attributable disability-adjusted life-years for 2019 were 
calculated and equivalent financial costs estimated. Estimated 
annual costs attributable to ACEs were equivalent to between 
1·1% and 6·0% of countries’ GDPs.
Implications of all the available evidence
ACEs are consistently related to many leading risk factors for, 
and causes of, ill health and estimates suggest that ACEs can 
impose major health and financial burdens on European 
nations. The extent and quality of data available to estimate 
costs varies widely across countries; thus, our findings here are 
not comparable between countries and estimates could be 
improved in most countries by improved data collection. 
Importantly, ACEs can be prevented and their costs avoided by 
investing in evidence-based early years, family, and resilience-
building programmes. The COVID-19 pandemic has disrupted 
many such services and increased risk factors for ACEs. Equally, 
the links between ACEs, health-harming behaviours, and 
chronic conditions mean ACEs might increase an individual’s 
susceptibility to COVID-19 and to the potential negative 
effects of restrictions imposed to control the virus. Investment 
choices made by governments towards pandemic recovery 
and future pandemic preparedness must recognise the 
importance of ACE prevention and support services in creating 
resilient societies.
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Methods 
Search strategy and selection criteria
In this systematic review and meta-analysis, we updated 
searches done by Bellis and colleagues10 in 2019 (covering 
Jan 1, 1990, to July 11, 2018) to identify additional 
quantitative studies (published July 11, 2018, to Sept 8, 2020; 
figure) that reported (1) prevalence of cumulative ACEs 
(ie, number of ACEs) and (2) risks of health outcomes 
associated with cumulative ACEs. We aimed to identify 
studies providing data that enabled an initial estimation of 
the cost of ACEs in various European countries. 
Six electronic databases (MEDLINE, CINAHL, PsycINFO, 
Applied Social Sciences Index and Abstracts, Criminal 
Justice Databases, and Education Resources Information 
Center) were searched with the terms “adverse childhood 
experience*”, “adverse childhood event*”, and “childhood 
adversit*” in title or abstract fields. Searches were done by 
FG, limited to journal articles published from July 11, 2018, 
with no language restrictions applied. Search results 
were extracted into Microsoft Excel. Searches were 
supplemented by use of author research networks. Title 
and abstract screening was undertaken by two reviewers 
(FG and EH) and full-text copies of relevant articles were 
obtained and screened by two reviewers (FG, EH, and KH) 
independently (figure).
Selected studies met the following criteria: reported on 
samples from WHO European region countries; focused 
on adults; used general population or non-high-risk 
samples; had a sample size of at least 1000 individuals; 
used a cumulative measure of at least three ACEs that 
included both direct (eg, maltreatment) and indirect 
(eg, household diffi culties) types (table 1); provided 
prevalence data for 0 ACEs, one ACE, and multiple ACEs 
(in categories permitting synthesis into a category of 
≥2 ACEs); and, for outcome studies, presented odds 
ratios (ORs), relative risks (RRs), or hazard ratios for one 
ACE and multiple ACEs (in categories permitting 
synthesis to a category of ≥2 ACEs) compared with those 
without ACEs. We contacted study authors for additional 
data to enable inclusion when possible. Studies considered 
for inclusion in Bellis and colleagues’ 2019 study10 were 
reconsidered for inclusion if they had contributed to 
European pooled risk ratios or met the inclusion criteria. 
Studies were selected for inclusion in prevalence and 
outcome estimates separately. For each estimate type, 
when more than one study reported the same data for the 
same sample, a single study was selected on the basis of 
larger sample size or data suitability. 12 health outcomes 
were included for which data were available from at least 
three studies. No specific definitions were used for 
outcomes (appendix p 1).
Data extraction and analysis 
Included studies were independently quality assessed 
(by KF, FG, and EH) using criteria covering sampling 
approach, bias, measurement of ACEs, response rate, 
refuser characteristics, sample description and, for 
outcome studies, data analysis (appendix p 3). Data on 
country, study type, participants, ACE mea surements, 
ACE prevalence, and outcome measure ments were 
extracted independently by two reviewers and checked by a 
third (KH, KF, FG, and EH; appendix pp 2–3).
To calculate pooled risk estimates, RRs or ORs (adjusted 
for sociodemographic data when available) were extracted 
 Figure: Study selection flowchart
The original search covered Jan 1, 1990, to July 11, 2018, and the updated search July 11, 2018, to Sept 8, 2020.  
ACE=adverse childhood experience. *Denotes the primary reason given but other reasons could apply. 
†Included case studies, corrections, and animal studies.
15 contributed to pooled relative risks
37 articles included
32 contributed to prevalence estimates
4137 references retrieved for title 
and abstract review  
2349 unique references screened in 
title and abstract review 
1788 duplicates removed 




 452 outside Europe
 660 inappropriate sample
 524 no relevant data or ACE
 measurement
 217 sample size too small
 27 other†
59 articles considered for inclusion 
208 excluded
 18 review
 80 outside Europe
 10 inappropriate sample
 41 no relevant data
 56 inappropriate ACE
 measurement
 2 sample size too small
 1 corrigendum
17 articles included20 European articles from original 
search
43 excluded 
 18 no or inappropriate ACE count 
 16 data used in other included 
study 
 6 no relevant data available 
 3 sample size too small
1 additional study identified 
from research networks
See Online for appendix
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from new outcome articles for each available ACE count 
level. ORs were transformed into RRs using RR=OR/
(1 − p0 + (p0 × OR)), where p0 is the baseline risk in the 
absence of ACEs.13 Two articles presented data from ACE 
studies using students in multiple countries;14,15 raw data 
were available from these student studies and thus each 
study was included as a separate sample with RRs 
calculated using generalised linear models. Raw data 
were also available for five UK studies combined in one 
article,12 and here study-level RRs were calculated by the 
authors when not included in previous estimates. For 
studies presenting multiple ACEs in more than one 
category (eg, 2–3 ACEs, ≥4 ACEs), these data were 
combined to an RR for at least two ACEs using a weighted 
mean method. Adjusted positive and negative counts by 
outcome and ACE category were calculated for use in 
meta-analyses. Existing calculations of positive and 
negative counts were used when studies had contributed 
to previous pooled RRs.10 For each outcome, pooled RRs 
(95% CIs) were generated through random effects 
models. Heterogeneity between studies was measured 
using I² statistic (table 2).16 Risk of publication bias 
was explored using Begg-Mazumdar and Egger tests 
and visual inspection of funnel plots when sufficient 
samples (>10)16 were available.
Country-level ACE prevalence was calculated for 
countries with sufficient prevalence data available 
(≥1000 individuals; table 3). To provide a level of correction 
for countries’ data coverage (ie, how representative 
available data were at a population level), country-level 
estimated marginal means and 95% CIs were calculated 
for each ACE category (0 ACE, 1 ACE, ≥2 ACEs) using a 
generalised linear model; weighting for sample size and 
incorporating data on sample country, sample age, 
sample representativeness, and number of ACEs 
measured. Estimated marginal means were adjusted 
towards samples that included all adult ages (vs younger 
[approximately <30 years], mid-age [approximately 
30–49 years], or older samples [approximately ≥50 years]), 
represented their target population demographics 
(vs non-representative samples); and measured more 
ACEs (≥8 vs <8).
Country-level PAFs were calculated for each outcome 
and ACE level using pooled RRs and country-level ACE 
prevalence according to:
where RRACE(exposure) is the pooled RR associated with ACEs 
and PACE(exposure) the proportion of the sample exposed.17
An adapted human capital methodology was used to 
calculate annual costs associated with each outcome.9,10,18 
For each country, 2019 disability-adjusted life-years 
(DALYs) estimates for matched Global Burden of Disease 
study outcomes (appendix p 1) were extracted for age 
categories 15–49 years, 50–69 years, and 70 years or older; 
and GDP and GDP per capita (2019 US$) were extracted 
from World Bank data. For each country, one DALY was 
assumed to equal GDP per capita (which ranged from 
$3659 in Ukraine to $81 994 in Switzerland); thus, costs 
for each outcome were calculated using DALYs*GDP 
per capita. This commonly used calculation reflects a 
year of life lost to disability or death being unproductive; 
with GDP per capita being the annual economic 
production value of each person in a population. Country-
level PAFs were applied to total DALYs and costs to 
estimate the economic value of DALYs lost for each 
outcome by ACE level. To generate a total cost of ACEs 
for each country, we excluded DALYs from risk factors 
that related to included causes to avoid double counting 
(eg, DALYs for smoking attributed to cancer; for each risk 
factor, DALYs relating to all included causes were 
excluded). The value of DALYs lost as a proportion of 
total national GDP was also calculated. In sensitivity 
analyses, country-level PAFs for each outcome were 
generated using upper and lower 95% CIs for pooled 
RRs, upper and lower estimates for country-level ACE 
prevalence, and overall ACE prevalence for all studies 
combined (appendix pp 8–35). Data editing and 
calculations were done in Microsoft Excel. Generalised 
linear models were done in SPSS (version 24). Meta-
analyses were done using StatsDirect (version 3.1.18).
Role of the funding source 
Members of the funding organisation supported 
identification of relevant studies through partner 
PAFACE2+ =PACE2+ × (RRACE2+ – 1)
PAFACE1 =PACE1 × (RRACE1 – 1)
(PACE0)+(PACE1 × RRACE1)+(PACE2+ × RRACE2+)
(PACE0)+(PACE1 × RRACE1)+(PACE2+ × RRACE2+)
Studies, n
Household substance abuse 30
Household mental illness 29
Parental separation or divorce 25
Physical abuse 24
Sexual abuse 21
Household member incarcerated or criminality 20
Exposure to domestic violence 17
Emotional, psychological, or verbal abuse 17
Parental death 15
Child welfare intervention (eg, out-of-home care) 14
Neglect 12
Family welfare or financial difficulties 10
Serious childhood illness or injury 5
Questions used to determine ACEs varied between studies. Other ACE types 
(measured in <3 studies) included childhood maltreatment, frequent fear of a 
family member, bullying, peer violence, victim of serious physical attack, 
frightening experience, family conflict or discord, parental affectionless control, 
parental dissatisfaction, parental illness or disability, separation from mother, 
other parental loss, sent away from home, death of a sibling, low parental concern 
for child’s education, child labour, hunger, or  residential instability. ACE=adverse 
childhood experience.
Table 1: ACE types measured by included studies
For GBD data see http://ghdx.
healthdata.org/gbd-results-tool
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net works, contributed to manuscript editing, and 
supported the decision to submit.
Results 
2349 unique references were identified. Full-text copies of 
267 (11·4%) articles were obtained and screened (figure). 
After 208 (77·9%) were excluded, 59 (22·1%) articles were 
considered for inclusion, along with 53 European articles 
drawn from the 223 articles considered in the 2019 
original search. 37 articles (20 from the original search 
and 17 from the updated search) were selected for 
inclusion (figure), 15 (40·5%) of which contributed to 
pooled RRs and 32 (86·5%) to ACE prevalence estimates. 
Study characteristics are shown in the appendix (pp 2–3). 
15 articles used UK samples;12,19–32 four used multi-country 
samples;14,15,33,34 two used samples from either Denmark,35,36 
Finland,37,38 Germany,39,40 the Netherlands,41,42 Norway,43,44 
Sweden,45,46 or Switzerland;47,48 and one each from 
Hungary,49 Ireland,50 Spain,51 and Ukraine.52 Study sample 
sizes ranged from 1059 individuals to 978 647 individuals 
(appendix pp 2–3). Samples were predominantly drawn 
from general populations, but student,14,15,39,43 primary 
care,24 and public sector employee37 samples were also 
included. The number and variety of ACEs collected by 
studies varied (table 1; appendix pp 4–5), as did definitions 
of several outcome measurements (appendix p 1). 
Outcome studies also varied in the level of adjustment for 
confounding, although most studies adjusted for 
demographic factors (appendix pp 2–3).
Table 2 presents pooled RRs for individuals with one 
ACE and two or more ACEs (vs 0 ACEs) for each outcome, 
with included sample numbers and sizes (forest plots are 
provided in the appendix pp 36–53). For all outcomes, 
pooled RRs increased from one ACE to two or more 
ACEs (table 2). RRs for one ACE ranged from 1·02 
(95% CI 0·97–1·06) for high BMI to 1·64 (1·43–1·88) for 
harmful alcohol use, and for two or more ACEs ranged 
from 1·07 (1·02–1·12) for high BMI to 3·72 (2·79–4·97) 
for interpersonal violence (table 2). The lower boundary 
for the 95% CI was below 1·0 for high BMI, interpersonal 
violence, cancer, type 2 diabetes, cardiovascular disease, 
and stroke with one ACE (table 2). We found considerable 
heterogeneity (I² >75%) between estimates for depression 
with one ACE, and for harmful alcohol use, smoking, 
illicit drug use, depression, anxiety, and type 2 diabetes 
with two or more ACEs (table 2). Begg-Mazumdar and 
Egger tests for bias were done for harmful alcohol use, 
smoking, and illicit drug use; results were only significant 
for harmful alcohol use with two or more ACEs (appendix 
pp 38, 41, 44). 
The 32 studies contributing to prevalence estimates 
provided sufficient data to calculate estimates for 
28 countries. Across all studies, adjusted prevalence of any 
ACE was 37·8% (one ACE, 22·6%; two or more ACEs, 
15·2%; n=2 181 712 individuals; table 3). Table 3 shows 
adjusted ACE prevalence for each country (upper and 
lower estimates and unadjusted figures are given in the 
appendix p 6). Adjusted proportions with any ACE ranged 
from 20·4% (North Macedonia) to 69·4% (Finland), and 
for two or more ACEs ranged from 4·2% (Greece) to 
38·8% (Finland; table 3). Distribution of ACE category 
among those with ACEs varied by country, with the 
proportion of individuals with any ACE reporting two or 
more ACEs ranging from 18·7% in Greece to 60·6% in 
Albania (table 3).
ACE prevalence estimates were used to calculate 
country-level PAFs due to ACEs for each outcome. PAFs 
were generated for one ACE and two or more ACEs and 
Samples, n* Individuals, n 1 ACE ≥2 ACEs









Harmful alcohol use 15 29 013 1·64 (1·43–1·88) 51·6% (0–71·8) 2·60 (2·07–3·27) 87·8% (81·8–91·1)
Smoking 17 32 173 1·27 (1·18–1·35) 31·7% (0–61·0) 1·74 (1·55–1·95) 83·1% (73·9–88·1)
Illicit drug use 17 32 513 1·59 (1·44–1·76) 48·6% (0–69·4) 2·63 (2·27–3·05) 84·0% (75·4–88·6)
High BMI† 5 12 586 1·02 (0·97–1·06) 0% (0–64·1) 1·07 (1·02–1·12) 36·2% (0–75·7)
Causes of ill health
Depression 6 1 473 863 1·44 (1·34–1·56) 86·1% (69·2–91·8) 2·19 (1·92–2·51) 95·3% (92·7–96·6)
Anxiety 3 6744 1·49 (1·27–1·74) 0% (0–72·9) 2·71 (1·89–3·89) 85·1% (24·9–93·3)
Interpersonal violence 5 15 267 1·31 (0·93–1·86) 50·3% (0–79·9) 3·72 (2·79–4·97) 65·6% (0–84·7)
Cancer 6 25 035 1·13 (0·95–1·33) 30% (0–71·7) 1·51 (1·28–1·78) 18% (0–67·6)
Type 2 diabetes 5 19 178 1·15 (0·89–1·48) 65·5% (0–84·7) 1·45 (1·08–1·94) 75·7% (11·6–88·2)
Cardiovascular disease 6 20 909 1·08 (0·99–1·19) 0% (0–61) 1·46 (1·25–1·69) 36·9% (0–73·9)
Stroke 4 12 769 1·28 (0·84–1·96) 0% (0–67·9) 1·76 (1·22–2·52) 0% (0–67·9)
Respiratory disease 5 19 215 1·32 (1·09–1·59) 0% (0–64·1) 2·26 (1·88–2·72) 0% (0–64·1)
ACE=adverse childhood experience. BMI=body-mass index. *See appendix (p 2) for included studies. †Defined in included studies as BMI ≥25 kg/m².
Table 2: Pooled relative risks for risk factors and causes of ill health
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summed to provide a total PAF due to ACEs. Total PAFs 
for each country and outcome are shown in the 
appendix (p 7). With the highest calculated ACE 
prevalence, Finland had the highest totalled PAFs due to 
ACEs across all outcomes, and Greece had the lowest 
(appendix p 7). In most countries, the largest PAFs due to 
ACEs were for interpersonal violence (range 14·7–53·5%); 
followed by harmful alcohol use (15·7–45·0%), illicit 
drug use (15·2–44·9%), and anxiety (13·9–44·8%; 
appendix p 7). High BMI had the lowest PAFs due to 
ACEs in all countries, ranging from 0·6% in Greece and 
North Macedonia to 3·1% in Finland (appendix p 7).
Country-level PAFs were applied to the equivalent 
number of DALYs for each outcome for 2019. 
ACE-attributable DALYs and associated costs for 
individual outcomes for each country are provided in the 
appendix (pp 8–35). In many countries, alcohol use, 
smoking, and cancer had the highest ACE-attributable 
costs (appendix pp 8–35). Table 4 presents total 
ACE-attributable DALYs (excluding those for risk factors 
relating to included causes) and country-level associated 
costs across all outcomes, and the equivalent proportion 
of national GDP this cost represents. The estimated 
number of DALYs attributable to ACEs ranged from 
13 000 in Montenegro to 4·3 million in Russia (table 4). 
ACE-attributable costs ranged from $0·1 billion in 
Montenegro to $129·4 billion in Germany (table 4). The 
equivalent proportion of GDP accounted for by ACE-
attributable costs ranged from 1·1% in Sweden and 
Turkey to 6·0% in Ukraine (median proportion 2·6% 
[IQR 1·5–3·2]; table 4).
For sensitivity analyses, in the lowest costed model, 
equivalent proportions of GDP accounted for by 
ACE-attributable costs ranged from 0·3% of GDP in 
Greece to 3·1% in Ukraine (appendix pp 8–35). In the 
upper costed model, these proportions ranged from 1·8% 
of GDP in Turkey to 8·9% in Ukraine (appendix pp 8–35).
Discussion 
This study identifies immense health and financial 
costs to European nations associated with ACEs and, 
consequently, highlights the importance of investing in 
safe and nurturing childhoods. Pooled RRs indicate that 
adults exposed to ACEs are more likely to engage in 
health-risk behaviours and develop physical and mental 
illnesses that reduce their years of healthy and productive 
life. Although the proportion of DALYs and ACE- 
associated costs for the 12 health outcomes studied varied 
between countries, in all countries combined ACE-
attributable costs exceeded 1% of national GDP, with the 
median proportion being 2·6%. This finding is similar to 
the previous European regional estimate of 2·7% (which 
used nine of 15 outcome studies included here).10 Highest 
PAFs due to ACEs were seen for violence, harmful 
alcohol use, illicit drug use, and mental illness (anxiety 
and depression). As well as being costly to individuals 
and society, these outcomes can represent ACEs for the 
offspring of affected adults, with ACEs known to have 
intergenerational effects.53 However, despite having 
lower PAFs, non-communicable diseases such as cancer 
and cardiovascular disease often had high costs to 
nations due to the high population burden of these 
conditions. Thus, in six countries, cancer carried the 
highest ACE-attributable costs of all conditions (Finland, 
Germany, Italy, Netherlands, Norway, and Switzerland).
Despite covering many leading health risks and causes 
of ill health in Europe, the actual burden of ACEs might 
be higher than indicated by our estimates. ACEs can 
stifle quality of life throughout the life course and forfeit 
the social benefits of healthy and resilient populations. 





Sample type* Adjusted prevalence
0 ACEs 1 ACE ≥2 ACEs
Albania 1 1395 Students 48·4% 20·3% 31·2%
Belgium 1 2618 Older adults 69·9% 23·4% 6·8%
Czech Republic 2 3327 Students and older adults 65·6% 20·4% 14·0%
Denmark 3 985 987 General† and older adults 57·0% 28·9% 14·1%
Finland 2 32 817 General† 30·6% 30·6% 38·8%
France 1 2174 Older adults 65·9% 25·6% 8·5%
Germany 3 5748 General†, students, and 
older adults
51·8% 22·6% 25·6%
Greece 1 2776 Older adults 77·3% 18·4% 4·2%
Hungary 1 1174 General† 75·0% 12·0% 12·9%
Ireland 1 6408 General† 53·2% 30·8% 16·1%
Italy 1 2399 Older adults 66·8% 24·9% 8·4%
Latvia 1 1003 Students 43·1% 25·9% 31·0%
Lithuania 1 1398 Students 64·0% 19·7% 16·3%
Moldova 1 1351 Students 68·9% 16·8% 14·3%
Montenegro 1 1084 Students 72·6% 16·5% 11·0%
Netherlands 3 12 228 General† and older adults 43·8% 25·8% 30·4%
North Macedonia 1 1200 Students 79·6% 14·3% 6·1%
Norway 3 23 591 General† and students 38·0% 32·4% 29·6%
Poland 2 3446 Students and older adults 63·5% 22·7% 13·8%
Romania 1 1542 Students 62·1% 20·3% 17·6%
Russia 1 1403 Students 72·7% 15·8% 11·6%
Serbia 1 2074 Students 73·2% 16·7% 10·0%
Spain 2 4216 General† and older adults 72·8% 20·2% 7·0%
Sweden 3 1 002 796 General† and older adults 75·7% 17·2% 7·1%
Switzerland 3 7957 General† and older adults 38·3% 29·0% 32·7%
Turkey 1 1763 Students 72·1% 16·5% 11·3%
Ukraine 2 2997 General† and students 50·3% 28·9% 20·8%
UK 11 64 840 General† and older adults 53·9% 23·0% 23·0%
Overall 55 2 181 712 ·· 62·3% 22·6% 15·2%
Adjusted ACE prevalence levels were calculated from available study data for the purpose of generating country-level 
population attributable fractions and are provided for information purposes. Figures should not be assumed to be 
nationally representative and compared between countries because of differences in data collection methods and 
sample characteristics (appendix p 2). ACE=adverse childhood experience. *Students includes samples recruited from 
educational institutions. Older adults comprised individuals predominantly older than 50 years. †Including general 
population samples and those from primary care (n=1, UK) and public sector (n=1, Finland) studies.
Table 3: Number of samples, total sample size, sample types, and resulting adjusted proportion within 
each ACE group by country
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other major societal costs, including low educational 
attainment, unemployment, crime, and social 
deprivation.54,55 For example, a UK study found each 
additional ACE was associated with a 9% earnings 
penalty, a 25% increased risk of welfare dependency, and 
a 27% increased risk of subjective poverty at age 
55 years.56 Equally, the harms associated with ACEs are 
not only realised in adulthood but can be seen from the 
earliest stages of life. Along with acute physical and 
emotional effects, children that have ACEs can show 
reduced cognitive and social development, reduced 
school engagement, early adoption of health-harming 
behaviours, and increased risk of health conditions and 
juvenile offending.55,57,58 Thus, the health, social, and 
economic benefits of effective action to prevent and 
respond to ACEs would emerge far sooner than would 
the adult health conditions examined here.
The importance of nurturing childhoods has 
increasingly dominated global health policy,59 with 
preventing violence against children, supporting families, 
and providing quality education being core features of the 
Sustainable Development Goals. The estimates reported 
here relate to a period before the COVID-19 pandemic 
and related restrictions. The pandemic might have 
increased conditions conducive to ACEs in families and 
reduced resilience-building opportunities if affected 
children are isolated in traumatic home settings and cut 
off from sources of support. The pandemic has also 
disrupted and diverted resources away from many 
services and programmes60 that help prevent ACEs, such 
as parenting programmes, socioeconomic development 
programmes, and youth support services. There is a 
concern that the resumption of such services will be 
deprioritised in the drive to catch up on clinical treatment 
and rebuild economic opportunity. Further, individuals 
who have had ACEs might have been particularly affected 
by the pandemic because of their increased risk both of 
chronic conditions that increase susceptibility to severe 
COVID–19 symptoms (eg, respiratory disease61) and of 
broader health harms associated with the pandemic 
(eg, poor mental health62). The differential impact of the 
pandemic on individuals with and without ACEs is yet to 
be quantified. However, preventing ACEs should 
contribute to reducing the health-harming behaviours 
and health conditions that can increase a population’s 
susceptibility to infection and thus potentially reduce 
health risks from future pandemics.
Our study had several limitations. Nationally rep-
resentative studies measuring cumulative ACEs and 
associations with health were not available for most 
countries, and although ACE prevalence data were 
identified for samples in 28 countries, in many these 
data were restricted to students or older adults (mainly 
aged ≥50 years). Study methodologies varied, as did the 
number and types of ACEs measured. Although we 
adjusted ACE prevalence calculations to provide some 
correction for data coverage, additional nationally 
representative data would strengthen country estimates. 
However, even where such data are available, further 
work is required to understand how accurately studies 
capture ACE exposure. Many included studies used 
retrospective, self-reported ACE measurement, which 
can be affected by recall and willingness to report, 
whereas those using prospectively measured ACEs or 
administrative data might miss ACEs that were 
unreported or unrecorded. Consequently, estimates are 
likely to be more reliable in countries with multiple 
studies using large representative samples and various 
methodological approaches, such as Denmark, Sweden 
and the UK.
Our study relied on ACE count measurements, which 
do not account for the timing, severity, or length of ACE 
exposure and assume each ACE type carries the same 
weight in influencing health.63 Further, although PAFs 
assume causal effects on outcomes, most included 
studies were cross-sectional and unable to measure 
causal relationships. Data from 18 countries contributed 
Population 
(millions)*








Albania 2·9 $5352·9 79·7 $0·4 2·8%
Belgium 11·5 $46 116·7 162·6 $7·5 1·4%
Czech Republic 10·7 $23 101·8 246·5 $5·7 2·3%
Denmark 5·8 $59 822·1 136·0 $8·1 2·3%
Finland 5·5 $48 685·9 225·2 $11·0 4·1%
France 67·1 $40 493·9 939·4 $38·0 1·4%
Germany 83·1 $46 258·9 2796·6 $129·4 3·4%
Greece 10·7 $19 582·5 123·8 $2·4 1·2%
Hungary 9·8 $16 475·7 239·1 $3·9 2·4%
Ireland 4·9 $78 661·0 97·8 $7·7 2·0%
Italy 60·3 $33 189·6 916·2 $30·4 1·5%
Latvia 1·9 $17 836·4 105·0 $1·9 5·5%
Lithuania 2·8 $19 455·5 93·0 $1·8 3·3%
Moldova 2·7 $4498·5 107·6 $0·5 4·0%
Montenegro 0·6 $8832·0 13·0 $0·1 2·1%
Netherlands 17·3 $52 447·8 536·2 $28·1 3·1%
North Macedonia 2·1 $6093·1 31·6 $0·2 1·5%
Norway 5·3 $75 419·6 145·7 $11·0 2·7%
Poland 38·0 $15 595·2 941·5 $14·7 2·5%
Romania 19·4 $12 919·5 660·5 $8·5 3·4%
Russia 144·4 $11 585·0 4312·4 $50·0 2·9%
Serbia 6·9 $7402·4 191·9 $1·4 2·8%
Spain 47·1 $29 613·7 565·9 $16·8 1·2%
Sweden 10·3 $51 610·1 117·9 $6·1 1·1%
Switzerland 8·6 $81 993·7 250·5 $20·5 2·9%
Turkey 83·4 $9042·5 926·5 $8·4 1·1%
Ukraine 44·4 $3659·0 2538·9 $9·3 6·0%
UK 66·8 $42 300·3 1858·7 $78·6 2·8%
Findings should not be assumed as comparable between countries and are affected by the characteristics of 
contributing studies (appendix p 2). ACE=adverse childhood experience. DALY=disability-adjusted life-year. GDP=gross 
domestic product (current US$). *2019 figures for total population according to World Bank data. 
Table 4: Total annual ACE-attributable DALYs and costs calculated for each country
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to pooled RRs, yet for several outcomes (eg, high BMI 
and violence) data were only available for UK samples 
and for others (eg, smoking) all non-UK studies used 
student populations. Although we used the same set of 
pooled RRs in calculations for each country, differences 
might exist between countries in associations between 
ACEs and outcomes. We also found differences in 
definitions of outcome measurements (appendix p 1) and 
levels of adjustment for confounding. Thus, although 
most outcome studies adjusted for demographic factors, 
including some level of socioeconomic measurement 
(appendix pp 2–3), such measurements varied and key 
demographic factors such as ethnicity were not always 
included. All these factors might have affected pooled 
estimates and heterogeneity seen between estimates. 
Thus, findings should not be compared across countries 
and figures should be viewed as estimates that are based 
on the best available data. Despite these limitations, our 
study provides a methodology for estimating the national 
burden of ACEs that could be enhanced in many 
countries by improved data collection and replicated 
elsewhere by collecting ACE data. Future work would 
benefit from subgroup analyses to account for differences 
in ACE prevalence and associations between ACEs and 
outcomes in different population groups.
To inform prevention and its effects, improved ACE 
measurement within countries and increased method-
ological consistency are necessary. WHO has already 
provided leadership towards such work, which in Europe 
has supported implementation of ACE studies among 
students in 13 countries.14,15 Elsewhere, ACE tools have 
been incorporated into routine population health surveys 
(eg, in the USA54 and Scotland21). However, existing ACE 
tools have received criticism for issues such as measuring 
a restricted range of ACEs and using simplistic scoring 
approaches.63 Greater  availability and comparability of 
epi demiological evidence on ACEs and their effects could 
be central to obtaining political commitment to invest in 
prevention. Thus, greater consensus is required on the 
ACEs that population studies should consider, how they 
should be measured, and among which populations.
ACEs are associated with major health and financial 
costs at local, national, and international levels. The initial 
annual estimates calculated here quantify ACE-attributable 
costs for various leading health risks and causes of ill 
health across different European countries. These 
estimates could be enhanced in many countries by 
improved data availability. However, the burden associated 
with ACEs goes well beyond those directly affected by poor 
health, affecting education, social, and criminal justice 
resources. The COVID-19 pandemic could have increased 
risk factors for ACEs, exacerbated inequalities, and led to 
potential economic recessions around the world.64,65 
Effective recovery from the pandemic will require nations 
to make investment choices that drive sustainable 
economic growth, increase health equity, and build 
population resilience to future pandemics. This study 
indicates the costs that individuals and societies pay when 
nations do not ensure a safe and nurturing beginning for 
all children. Deficits in child and family support created by 
COVID-19 must be urgently addressed. However, after the 
pandemic we should go further, investing in ACE-free 
childhoods that propel individuals on to healthy, social, 
and prosperous life courses that also leave individuals 
more physically and mentally resilient to future pandemics.
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